| DESCRIPTION OF RUNXKINDREDS

| Family A -RUNX1 deletion associated with T-lymphoblastic lymphoma
A 22-year-old man, patient A, proband for Family A (Genogram A, IV.1) presented with cervical lymphadenopathy. He had a background of chronic thrombocytopenia without an associated bleeding phenotype, International Society of Thrombosis and Haemostasis Bleeding Assessment Tool (ISTH-BAT) score of 1. 1 On initial assessment, he had a hemoglobin of 157 g/L, white cell count of 9.5 × 10 9 /L, and platelet count of 126 × 10 9 /L with a normal mean platelet volume (MPV) of 9.2 fL ( Table 1 ). Lymph node core biopsy showed diffuse proliferation of lymphoblasts with fine chromatin, positive on immunohistochemistry for pan-T-cell antigens CD3, CD4, and CD5 and the blastic marker terminal deoxynucleotidyl transferase (TdT) but not for CD34. Bone marrow biopsy was normocellular with mild dysplasia present in megakaryocytes but no evidence of acute lymphoblastic leukemia (ALL) infiltration. Tissue culture of the lymph node tissue failed to yield metaphases, but cytogenetic analysis of bone marrow demonstrated a normal 46,XY karyotype. Taken together, these features were consistent with a diagnosis of T-lymphoblastic lymphoma. Patient A's mother (Genogram A, III.2) also had chronic thrombocytopenia (baseline platelet count, 70 × 10 9 /L) and ALL (French-American-British Classification, L1; unspecified lineage, normal karyotype) at age 29, with subsequent development of a therapy-related myelodysplastic syndrome (MDS) decades after her initial chemotherapy exposure, necessitating matched unrelated donor (MUD) allograft at age 60. Her paternal cousin (Genogram A, III.3) had died of acute myeloid leukemia (AML) in his first decade of life, and multiple family members had previously received a diagnosis of chronic thrombocytopenia. Whole exome sequencing studies were performed on the index case, and the mother did not identify a pathogenic variant responsible for the presentation. Diagnosis of FPDMM in Patient A and his mother was then achieved by single-nucleotide polymorphism array that demonstrated a 0.81-Mb deletion on chromosome 21 (21q22.12), which included exons 1-3 of RUNX1 (see Appendix S1). A constitutional deletion was confirmed with absence of the 5′probe of the RUNX1 fluorescence in situ hybridization (FISH) assay using patient-derived cultured fibroblasts and was supported by increased MYH10 expression in platelet lysates by western blot. 2 Limiting diagnostic consideration of underlying FPDMM to patients with thrombocytopenia and family history of myeloid malignancy alone may potentially miss families with less frequently reported lymphoid presentations. 
| Family B -RUNX1 variant associated with eosinophilic leukemia
| Family C -RUNX1 variant and microthrombocytopenia
| DISCUSSION
Our case series of atypical presentations further confirms the significant clinical heterogeneity in FPDMM. [3] [4] [5] Various mutations have been described causing RUNX1-associated FPDMM and commonly include point mutations 6 (Family C), but can also be due to intragenic deletions (Family A), which have been reported in only 6
FPDMM cases to date. 7, 8 The latter necessitate techniques beyond conventional short-read NGS and Sanger sequencing for detection.
Germline RUNX1 mutation alone is insufficient for development of malignancy, and additional secondary mutations with subsequent clonal evolution likely underlie the path to leukemogenesis. 9 Subsequent secondary mutations presumably alter the presenting phenotype of the disease -here, in Patient B, we describe KIT D618V that is typically associated with mast cell excess, but there is limited murine evidence that altered RUNX1 function may also alter lineage differentiation. 10 There is wide variability in the degree of thrombocytopenia in FPDMM, and normal platelet counts have also been reported. 4 Like other myeloid neoplasms with germline predisposition and preexisting platelet disorders (ETV6 and ANKRD26), platelet size is typically normal to slightly enlarged. 11 To our knowledge, Family C is the first reported family with FPDMM and reduced platelet size. Despite the presence of microthrombocytopenia, differentials of Wiskott-Aldrich syndrome (WAS) and X-linked thrombocytopenia were considered unlikely, given the autosomal dominant pattern of thrombocytopenia seen in Family C (Figure 1 ). WAS-, FYB-, and CYCS-related thrombocytopenia, which are thrombocytopenias associated with small platelets, 11 as well as, ANKRD26/ETV6 were excluded through our NGS panel and/or subsequent Sanger sequencing. However, as whole genome sequencing was not performed, other potentially contributing variants have not been excluded.
RUNX1 is a key hematopoietic transcription factor that silences the expression of MYH10 during maturation of megakaryocytes, 12 and increased platelet MYH10 expression has been identified as a marker of RUNX1 mutation. highlighting the need to screen widely across the family once a diagnosis of FPDMM is made.
There are emerging guidelines to direct the testing of patients at risk of inherited myeloid malignancy 15 , though these remain broad and not specific to FPDMM. As illustrated in the above cases, we are still only beginning to understand the breadth of phenotype of RUNX1-associated FPDMM. As such, we propose that all patients with chronic thrombocytopenia and a family history of any hematologic MDS/malignancy be considered for testing. Furthermore, in our experience, there may be marked variability in platelet numbers/size such that all family members should be screened regardless of platelet count in the setting of known hematologic malignancy and a familial history of thrombocytopenia. In patients being considered for allogeneic stem cell transplant, we recommend RUNX1 mutation testing via nonhematopoietic germline tissue such as skin fibroblasts.
In patients found to have RUNX1 mutations, genetic counseling should be offered, and kindred should be tested given therapeutic implications of affected family members becoming allogeneic stem cell donors.
Detection of RUNX1, whose kindred have yet to manifest with any MDS/AML poses a dilemma. Evolving knowledge regarding roles of cooperating "second-hit" mutations and the effects of RUNX1 dosage in clonal evolution 2,9 may assist in predicting risk of malignancy in such individuals. Given the potential long latency period between diagnosis of RUNX1-associated thrombocytopenia to development of malignancy and its variable phenotypic manifestations, establishing the frequency and nature of monitoring investigations remains an ongoing challenge.
In patients found to have RUNX1 mutations, no consensus guidelines have been developed for surveillance to date. In line with others, 16, 17 we recommend close surveillance with 6 to 12 monthly full blood counts and annual clinical review, with consideration for bone marrow examination with any concerning changes in hematologic parameters. Ultimately, with increasing recognition of this disorder and availability of technologies to detect both driver and secondary mutations in leukemogenesis, further structured management approaches may be achieved. 
